UNSPSC 51385405: Cinchophen piperazine

This classification denotes a nonsteroidal antiinflammatory drug C16H11NO2.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O65C9QHG6D, chemically known as 4-quinolinecarboxylic acid, 2-phenyl-, compd. with piperazine (1:1), but more generally known as cinchophen piperazine, which bears US NIH Compound Identifier 71300650. European Medicines Agency schedules Cinchophen piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01308MIG.

Most nations, for tariff and trade purposes, schedule cinchophen piperazine under HS 29334910 and SITC 51575. As of Q4 2014, CINCHOPHEN PIPERAZINE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)C2CC(C3CCCCC3N2)C(=O)O.C1CNCCN1.

UNSPSC 51385405 Cinchophen piperazine is a Commodity code with minimal recent state and local procurement activity aligned to its nominal pharmaceutical scope. The single recent opportunity in the dataset—Seminole County, Florida's IFB 60459723LAS—targets naloxone and drug deactivation systems, which fall outside the code's stated product line and suggest the code may be misapplied in state and local sourcing systems or used as a placeholder for related pharmaceutical and medical supply categories that lack more precise UNSPSC alignment.

Seminole County posted the naloxone and drug deactivation systems procurement on June 30, 2026, with a response deadline of July 26, 2023 (the source contains an inconsistent date pair), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The county required electronic bid submission through its e-Procurement Portal, with vendors responsible for all shipping and delivery costs, drug-free workplace certification, and E-Verify compliance. The contract offered an initial two-year term with one-year renewal option and included a three-month probationary termination clause. No explicit set-aside designations were identified, though the procurement noted potential FEMA funding with associated federal compliance requirements. The absence of other recent opportunities under this code indicates limited current state and local sourcing activity in this pharmaceutical commodity category, or broader misalignment between the code taxonomy and how state and local jurisdictions tag medical supply procurements.